摘要
对中、晚期肝癌而不能手术治疗者肝动脉注射５－氟脲嘧啶的药代动力学进行考察。方祛：采用ＨＰＬＣ法对２０名肝癌患者肝动脉注射１０００ｍｇ ５－氟脲嘧啶行肝动脉栓塞治疗后的血药浓度进行测定，结果经３ｐ９７药代动力学计算程序处理拟合。结果：符合一室模型，５－氟脲嘧啶在中、晚期肝癌患者中的主要药代动力学参数分别为： Ｃ０是３２．９３±２１．７６ｍｇ·Ｌ－１， Ｋｅ为０．０６０４７ ± ０．００９１９ｍｉｎ－１， Ｖｃ为４１．８６± ２０．６０Ｌ； Ｔ１／２是１１．７１± １．７５ｍｉｎ； ＡＵＣ是５３２．６３± ３１９．７４ｍｉｎ·ｍｇ·Ｌ－１； ＣＬ为２．４４ ±１．０９Ｌ·ｍｉｎ－１。结论： ５－氟脲嘧啶在中、晚期肝癌患者中的半衰期与文献报道［１］的 １０－ ２０ｍｉｎ基本一致，这说明 ５－氟脲嘧啶的代谢在中、 晚期肝癌患者中不受影响。
OBJECTIVE: To determine the plasma concentration of 5-fluorouracil in hepatic carcinoma patients. METHODS: After injection of 1000mg 5- fluorouracil by hepatic arterial route and study the characteristic of parmacokinetics in 20 patients. RESULTS: The results showed one-compartment open model after calculating by 3p97 program soft ware. The pharmacokinetic parameters were as follow : C0 =32.93 ±21.76mg·L-1; Ke=0.06 ± 0.01min-1; Vc=41.86 ±20.60L; T1/2=11.71±1.75min; AUC=532.63 ±319.74min·mg· L-1; CL=2.44 ±1 .09L·min-1. CONCLUSION: The pharmacokinetics parameters were the same as reported in the references. They were not influenced by the hepatic carcinoma.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第4期280-282,共3页
The Chinese Journal of Clinical Pharmacology
基金
本课题属"九五"国家医学科技攻关项目!专题号96-907-03-01)
